BioNTech Ownership
| BNTX Stock | USD 121.16 3.14 2.53% |
Shares in Circulation | First Issued 2018-09-30 | Previous Quarter 240.4 M | Current Value 244.6 M | Avarage Shares Outstanding 241.8 M | Quarterly Volatility 13.6 M |
BioNTech |
BioNTech Stock Ownership Analysis
About 62.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.49. Some equities with similar Price to Book (P/B) outperform the market in the long run. BioNTech SE has Price/Earnings To Growth (PEG) ratio of 0.04. The entity recorded a loss per share of 2.02. The firm last dividend was issued on the 2nd of June 2022. BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany. Biontech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3082 people. For more info on BioNTech SE please contact Ugur MD at 49 6131 9084 0 or go to https://www.biontech.de.BioNTech Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as BioNTech is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading BioNTech SE backward and forwards among themselves. BioNTech's institutional investor refers to the entity that pools money to purchase BioNTech's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Balyasny Asset Management Llc | 2024-09-30 | 620.5 K | Fred Alger Management, Llc | 2024-09-30 | 500.8 K | Dekabank Deutsche Girozentrale | 2024-09-30 | 481.4 K | First Trust Advisors L.p. | 2024-09-30 | 451.2 K | Quinn Opportunity Partners Llc | 2024-09-30 | 404.5 K | Voloridge Investment Management, Llc | 2024-09-30 | 400.3 K | Amundi | 2024-09-30 | 366.7 K | Point72 Asset Management, L.p. | 2024-09-30 | 362 K | Squarepoint Ops Llc | 2024-09-30 | 324.7 K | Baillie Gifford & Co Limited. | 2024-09-30 | 8.3 M | Fmr Inc | 2024-09-30 | 6.3 M |
BioNTech's latest congressional trading
Congressional trading in companies like BioNTech SE, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in BioNTech by those in governmental positions are based on the same information available to the general public.
| 2024-10-04 | Representative Josh Gottheimer | Acquired Under $15K | Verify | ||
| 2024-10-03 | Representative Josh Gottheimer | Acquired Under $15K | Verify | ||
| 2024-09-11 | Representative Josh Gottheimer | Acquired Under $15K | Verify |
BioNTech Outstanding Bonds
BioNTech issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. BioNTech SE uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most BioNTech bonds can be classified according to their maturity, which is the date when BioNTech SE has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View |
BioNTech Corporate Filings
6K | 14th of January 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for BioNTech Stock Analysis
When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.